{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:00:39Z","timestamp":1791892839905,"version":"4.3.4"},"reference-count":3,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"abstract":"\n Background<\/jats:title>\n Deucravacitinib, a tyrosine kinase 2 inhibitor, has shown efficacy and tolerability in moderate-to-severe psoriasis. However, evidence on switching from deucravacitinib to an interleukin-23 inhibitor is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n We examined outcomes after switching from deucravacitinib to the anti-interleukin-23p19 antibody tildrakizumab.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a single-center retrospective study of 15 adults (aged \u226518 years) with psoriasis who showed an insufficient response to \u226516 weeks of deucravacitinib 6 mg. Insufficient response was defined as < 75% improvement of psoriasis area and severity index (PASI) from baseline, or a static physician\u2019s global assessment (sPGA) score of \u22652. After switching, patients received tildrakizumab 100 mg at weeks 0 and 4, followed by every 12 weeks. We assessed PASI, sPGA, and the dermatology life quality index (DLQI) at weeks 4, 16, and 28.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n At week 28, the mean percent reductions from baseline were 89.0% for PASI and 77.2% for DLQI. The achievement rates of PASI 75, PASI 90, PASI 100, and sPGA 0\/1 at week 28 were 88.9%, 55.6%, 44.4%, and 77.8%, respectively. The achievement rates of PASI \u22643, PASI \u22642, PASI \u22641, and DLQI 0\/1 at week 28 were 88.9%, 77.8%, 55.6%, and 50.0%, respectively. Three treatment-related adverse events (AEs) occurred; eczema in 2 patients (13.3%) and arthralgia in 1 patient (6.7%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These preliminary findings suggest that tildrakizumab may be a treatment option for patients with an insufficient response to deucravacitinib.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/24755303261497686","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:36:18Z","timestamp":1791642978000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Switching From Deucravacitinib to Tildrakizumab in Psoriasis: A 28-Week Real-World Study"],"prefix":"10.1177","author":[{"given":"Yohei","family":"Takahashi","sequence":"first","affiliation":[{"name":"Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"additional","affiliation":[{"name":"Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Yoneyama","sequence":"additional","affiliation":[{"name":"Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Shiba","sequence":"additional","affiliation":[{"name":"Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2307489"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303261497686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303261497686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303261497686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:16:56Z","timestamp":1791890216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303261497686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":3,"alternative-id":["10.1177\/24755303261497686"],"URL":"https:\/\/doi.org\/10.1177\/24755303261497686","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"article-number":"24755303261497686"}}